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Maternal factor V Leiden mutation is associated with HELLP
syndrome in Caucasian women
Abstract
Objective. There is growing evidence that hypertensive pregnancy complications and other adverse
pregnancy outcomes are associated with the presence of inherited or acquired thrombophilias. As
hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome is one of the most severe forms of
pre-eclampsia we aimed to assess the prevalence of the factor V Leiden, the prothrombin 20210G >A
mutation and the methylenetetrahydrofolate reductase (MTHFR) 677C >T polymorphism in women
with HELLP syndrome and in their fetuses from the same index pregnancy. Design. The study was
performed retrospectively in a case-control design. Sample. Seventy-one mother-child pairs with
HELLP syndrome and 79 control mother-child pairs with uncomplicated pregnancies were included in
the study. Methods. Genotyping of the three thrombophilic mutations was performed using the
LightCycler technology. The chi-squared test was used for statistical analysis. Main outcome measures
were maternal and fetal genotypes and their correlation with clinical parameters. Results. Maternal
heterozygosity for factor V Leiden was significantly more prevalent in the HELLP group than in
controls (OR 4.45, 95% CI 1.31-15.31). No significant association was observed for maternal
prothrombin mutation or MTHFR polymorphism (p=0.894, p=0.189, respectively). The fetal genotype
was not associated with HELLP syndrome for any of the three mutations investigated. Analysis of
gene-gene interactions and genotype-phenotype correlation with respect to clinical parameters and
perinatal outcome revealed no further differences. Conclusions. Our study confirms that women
heterozygous for factor V Leiden have an increased risk of developing HELLP syndrome, while the
most frequent mutations of the prothrombin and MTHFR gene do not play a major role in the
pathogenesis of HELLP syndrome.
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Abstract 
Objective: There is growing evidence that hypertensive pregnancy complications and other 
adverse pregnancy outcomes are associated with the presence of inherited or acquired 
thrombophilias. As HELLP syndrome is one of the most severe forms of pre-eclampsia we 
aimed to assess the prevalence of the factor V Leiden, the prothrombin 20210G>A mutation 
and the MTHFR 677C>T polymorphism in women with HELLP syndrome and in their 
fetuses from the same index pregnancy.  
Design: The study was performed retrospectively in a cas-control design.  Sample: 71 mother-
child pairs with HELLP syndrome and 79 control mother-child pairs with uncomplicated 
pregnancies were included in the study. Methods: Genotyping of the three thrombophilic 
mutations was performed using the LightCycler technology. The chi-squared test was used for 
statistical analysis. Main outcome measures: Maternal and fetal genotypes and their 
correlation with clinical parameters.  
Results: Maternal heterozygosity for factor V Leiden was significantly more prevalent in the 
HELLP group than in controls (OR 4.45, 95%CI 1.31-15.31). No significant association was 
observed for maternal prothrombin mutation or MTHFR polymorphism (p=0.894, p=0.189 
resp.). The fetal genotype was not associated with HELLP syndrome for any of the three 
mutations investigated. Analysis of gene-gene interactions and genotype-phenotype 
correlation with respect to clinical parameters and perinatal outcome revealed no further 
differences.   
Conclusions: Our study confirms that women heterozygous for factor V Leiden have an 
increased risk of developing HELLP syndrome, while the most frequent mutations of the 
prothrombin and MTHFR gene do not play a major role in the pathogenesis of HELLP 
syndrome.  
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Introduction 
HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome is a life-threatening form 
of pre-eclampsia, complicating about 0.17 - 0.8% of all live births (1). Diagnosis of HELLP is 
based on the evidence of intravascular hemolysis, impaired liver function and 
thrombocytopenia. Approximately 15% of women with pre-eclampsia/eclampsia show the 
complete spectrum of HELLP syndrome and thus have an increased risk for significant 
perinatal morbidity and mortality, both maternal and fetal (2).  
There is growing evidence that hypertensive pregnancy complications and other adverse 
pregnancy outcomes are associated with the presence of inherited or acquired thrombophilias 
(3;4). However, the results of single studies remain controversial. Most of the inherited 
thrombophilias are found in the protein C system and affect the physiological balance 
between pro- and anticoagulant factors (5). Inherited resistance to activated protein C (APC) 
is known as risk factor for thrombosis. A single point mutation in the gene for factor V (G to 
A transition at nucleotide position 1691, factor V Leiden mutation), which predicts 
replacement of Arg(R)506 in the APC-cleavage site with a Gln(Q) and results in an impaired 
degradation of factor V, accounts for more than 90% of the cases of APC-resistance (6). The 
prevalence of factor V Leiden mutation in the normal population ranges from 3 to 7% in 
Europe and the USA (7).   
The prothrombin gene mutation (20210G>A) is a second common genetic risk factor for 
thrombosis, leading to an increased plasma concentration of prothrombin with a subsequently 
higher rate of fibrin formation (8). In Europe the carrier frequency of the prothrombin 
mutation is reported to be 1-4% with a nearly twofold higher prevalence in Southern than in 
Northern Europe (9).  
Homozygosity for the polymorphism 677C>T in the methylenetetrahydrofolate reductase 
(MTHFR) gene is associated with hyperhomocysteinemia and may thus increase the risk for 
vascular disorders (10). The MTHFR 677C>T polymorphism can be found in  homozygous 
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state in about 14% of the general Caucasian population with higher carrier rates in Southern 
compared to Northern Europe (11). 
Over the last decade more than 70 studies including several meta-analyses have investigated 
the prevalence of thrombophilic gene mutations in pre-eclampsia, yielding contradictory 
results [for review see (4;12)]. Only 14 studies have addressed the association between these 
mutations and the development of HELLP syndrome, also reporting conflicting data (13-26).  
Most of these studies have included a small number of HELLP patients and have not assessed 
the fetal genotype. Furthermore, data from HELLP patients are often included in the results 
for pre-eclampsia patients.  
In this study we aimed to assess the prevalence of the most common inherited thrombophilias 
factor V Leiden, prothrombin 20210G>A and MTHFR 677C>T in a well-defined cohort of 
Caucasian women with a history of HELLP syndrome compared to healthy female controls. 
As vascular features of the placenta are thought to be involved in the pathogenesis of pre-
eclampsia, and as the placenta is of fetal origin (27;28), fetuses from the index pregnancies 
were also genotyped for the three common thrombophilic mutations in order to determine 
whether a paternal contribution is of central importance.   
 
Materials and Methods 
Study cohort 
71 women with HELLP syndrome and their children from the index pregnancy were included 
in our study. Patients were recruited at the Department of Obstetrics and Gynecology, Aachen 
University Hospital, and nationwide by the German pre-eclampsia society. 79 healthy mother-
child-pairs with uncomplicated pregnancies who delivered at Aachen Univeristy Hospital or 
obstetric departments in the surrounding area were enrolled as controls. All subjects were of 
white Caucasian origin. The diagnosis of HELLP syndrome was based on the presence of 
hemolytic anemia (serum haptoglobin levels < 0.3 g/L or serum lactate dehydrogenase (LDH) 
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> 300 IU/L), elevated liver enzymes (elevation of serum aspartate aminotransferase (AST) or 
serum alanine aminotransferase (ALT) over norm), and evidence of thrombocytopenia, 
defined as a platelet count of  < 100.000/µl. The study was approved by the Institutional 
Ethics Committee and informed consent was obtained from all subjects.  
 
DNA studies 
Genomic DNA was isolated from blood leukocytes as described by Miller et al. (29). Analysis 
of the defined point mutations of factor V, prothrombin and MTHFR was performed using the 
LightCycler technology (Roche Diagnostics, Mannheim, Germany). For analysis of the 
corresponding sites in human factor V (1691G>A) and human prothrombin (20210G>A) 
commercially available kits (LightCycler-Factor V Leiden mutation detection kit, 
LightCycler-Prothrombin (20210G>A) mutation detection kit/ Roche, Mannheim, Germany) 
were used. MTHFR 677C>T genotyping was performed as described by von Ahsen et al. (30) 
with slight modifications. In brief, a 198 bp fragment containing the mutation site was 
amplified with 0.1 µM primer MTHFR-rev [5´-d(AGG ACG GTG CGG TGA GAG TG)-3´] 
and 0.5 µM primer MTHFR-for [5´-d(TGA AGG AGA AGG TGT CT*G CGG GA)-3´] 
carrying a LC-Red640 group at T*. PCR reaction was performed in a 1x “LC™-DNA Master 
Hybridization Probes” including additional 1.5 mM MgCl2 and 0.1 µM primer MTHFR-probe 
[5´-d(AGC TGC GTG ATG ATG AAA TCG GCT CC-Fluorescein)-3´]. Samples were 
initially denaturated for 30 sec at 95°C (ramp rate 20°C/sec) and amplified for 55 cycles of 0 
sec at 94°C (ramp rate 20°C/sec), 5 sec at 50°C (ramp rate 20°C/sec), and 5 sec at 72°C (ramp 
rate 20°C/sec). The melting curve analysis was performed in 1 cycle of 95°C for 0 sec and 
40°C for 1 min, each with a temperature transition rate of 20°C/sec, and then ramping to 80°C 
with a transition rate of 0.1°C/sec and continuous fluorescence measurement. Each run 
included DNA controls of all genotypes (verified by sequencing) and a water control. All 
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primers were obtained from Metabion (Martinsried, Germany) or TipMOL (Berlin, 
Germany).  
 
Statistical analysis 
Results for the two groups were compared by using the χ2-test. p-values < 0.05 were regarded 
as statistically significant. Statistical analyses were performed with SPSS for Windows®. 
 
Results 
Clinical characteristics of the study groups are shown in Table 1. 89% of HELLP patients 
presented with signs of pre-eclampsia according to ISSHP criteria (blood pressure ≥ 140/90 
mmHg after 20th week of gestation on at least two independent occasions accompanied by 
proteinuria ≥ 0.3 g/ 24 h or ≥ 1 g/l (≥ 2+ on urinary dipstick)). The number of primiparous 
women was higher in the HELLP group (88.7% vs. 65.8%). Furthermore, cases and controls 
differed significantly with respect to blood pressure, gestational age at delivery and birth 
weight of the infants.  
Maternal genotype distribution for the mutations in the prothrombin and factor V gene and the 
polymorphism in the MTHFR gene is presented in Table 2. Heterozygosity for factor V 
1691G>A mutation was more prevalent in HELLP patients than in controls (16.9% vs. 3.8%, 
OR 4.45, 95%CI 1.31-15.13, p=0.006). None of the patients or controls had a homozygous 
mutation of factor V Leiden.   
No differences were observed in maternal genotype frequencies of prothrombin 20210G>A 
mutation (p=0.894) or MTHFR 677C>T polymorphism (p=0.189). 
Fetal blood samples were obtained from all of the 71 HELLP pregnancies and from 78 of the 
control pregnancies. For technical reasons genotyping was not possible in all samples. Fetal 
genotypes were not associated with maternal HELLP syndrome for any of the three mutations 
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investigated (Table 3), thus excluding a relevant paternal contribution to the development of 
the disease.  
In order to evaluate the influence of thrombophilic mutations on disease severity and perinatal 
outcomes, genotype-phenotype correlation was performed for all three mutations separately in 
the HELLP subjects following the items in table 1. No significant association was found for 
any of the clinical variables investigated: gestational age at delivery, infant´s birth weight, 
systolic and diastolic blood pressure, platelet count, liver enzymes (AST, ALT) and hemolysis 
(LDH).  
Furthermore, analyis of gene-gene interactions in the mother, in the fetus and between mother 
and fetus was performed. In the HELLP group, neither mothers nor children were compound 
heterozygous for factor V Leiden or the prothrombin gene mutation whereas among the 
controls, one child and one mother were compound heterozygous. Only one child in the 
HELLP group carried the MTHFR-677-TT genotype and was heterozygous for the 
prothrombin gene mutation. The combination of heterozygous factor V Leiden and 
homozygosity for MTHFR – 677-T was not found at all in our study population.  Regarding 
the gene-gene interactions between mother and fetus, the frequency of mothers who had 
inherited the mutant allele to their offspring was the same in patients and controls for the tree 
mutations investigated.   
 
Discussion 
To our knowledge this is the largest study published so far on the relation between HELLP 
syndrome and the thrombophilic gene mutations factor V Leiden, prothrombin 20210G>A 
MTHFR in mothers and fetuses. The post hoc statistical power calculation revealed that given 
17% heterozygosity in the HELLP group and 4% in the control population and accepting an 
alpha error level of 10%, the statistical power would be as high as 91%.   
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Previous association studies on thrombophilic genotypes and HELLP syndrome are 
summarized in Table 4 (13-26).  Most of them were limited to a small sample size and 
genotyping was not done simultaneously for all of the three most common inherited 
thrombophilias. However, in line with our results, an increased risk for HELLP syndrome in 
factor V Leiden carriers was reported in two Caucasian samples (22;25). In contrast to most 
of the other studies, Nagy et al. (20) reported a significantly increased prevalence of the 
MTHFR 677TT genotype in Caucasian HELLP patients from Hungary. Demir et al. (15) also 
found a positive association for the MTHFR 677C>T polymorphism in Turkish women with 
hypertensive pregnancy disorders including 20 patients with HELLP syndrome, but as the 
latter subgroup has not been analyzed separately, a comparison with other studies on HELLP 
syndrome and thrombophilia is rather difficult. In two other studies cited in Table 4, HELLP 
subgroup analysis has not been performed either (16;24). Furthermore, some studies have 
included patients from heterogeneous ethnic backgrounds (19;24), a critical point considering 
the great differences in allelic frequencies across populations (31).   
In contrast to the HELLP syndrome, the relation between pre-eclampsia in general and 
inherited thrombophilia has been more extensively investigated. In a recent review and meta-
analysis including studies published in English between 1980 and June 2003, Robertson et al. 
(4) described an increased risk of pre-eclampsia for heterozygous factor V Leiden (OR 
2.19,95%CI 1.46-3.27), heterozygous prothrombin 20210G>A (OR 2.54, 95%CI 1.52-4.23) 
and homozygous MTHFR 677C>T (OR 1.37, 95%CI 1.07-1.76). In 2005 Lin et al. performed 
another meta-analysis including studies published up to November 2002 (32). A two-fold 
increase in pre-eclampsia risk was demonstrated for the factor V Leiden mutation (OR 1.81, 
95%CI 1.14-2.87) while no effects were detected for prothrombin G mutation or 
homozygosity for MTHFR 677C>T. However, when the more recent studies published up to 
the end of 2007 are additionally considered, there is no evidence for a major effect of these 
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common thrombophilias on pre-eclampsia risk as most studies failed to demonstrate a 
significant association (31).   
Fetal genes related to vascular conditions are also supposed to influence the risk of pre-
eclampsia and HELLP because the placenta is of fetal origin and vascular features of the 
placenta are thought to be involved in the pathogenesis of these disorders (27;28). Therefore 
we assessed the fetal genotype for factor V Leiden, prothrombin 20210G>A and MTHFR 
677C>T. No influence on maternal risk of HELLP syndrome was observed.  
Several studies have addressed the role of fetal inherited thrombophilias in pre-eclampsia, 
only three of them have included a small number of HELLP pregnancies (Table 5)(19, 
23,28,33-38). On the whole, there was no evidence for a strong association. Nevertheless, 
Dizon-Townson et al.(35) found a trend towards an increase of maternal pre-eclampsia among 
fetal factor V Leiden carriers (p=0.06) which became significant when the cases were 
separated according to ethnicity. In African-American and Hispanic mothers of fetal factor V 
Leiden carriers, pre-eclampsia revealed to be significantly more frequent than in whites 
(p=0.04).  Furthermore, Anteby et al. (33) showed that fetal factor V Leiden and prothrombin 
mutations may lead to a more severe course of pre-eclampsia, intrauterine growth-restriction 
and placental abruption: Fetuses with factor V Leiden or prothrombin mutation were born 
earlier (p=0.04) and weighed less (p=0.02) than fetuses without these thrombophilic 
mutations. Thus a certain fetal impact on maternal pre-eclampsia and other severe obstetric 
complications may not be completely ruled out. Our results clearly show that there is no 
paternal effect in addition to maternal inheritance of factor V Leiden mutation which should 
be found with an increased frequency in the fetuses since the mutation is more prevalent in 
mothers with HELLP syndrome.   
In summary, our data confirm that Caucasian women carrying a heterozygous factor V Leiden 
mutation have an increased risk of developing HELLP syndrome (OR 4.45). In contrast, no 
significant association was found for prothrombin 20210G>A mutation and MTHFR 677C>T 
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polymorphism. No further differences were detected when thrombophilic genotypes were 
related to the clinical features of HELLP syndrome and perinatal outcome. Moreover, there 
was no evidence for a fetal genetic influence on the mother´s risk of developing HELLP 
syndrome. We further may conclude from our study that gene-gene interactions do not have a 
major impact on the role of thrombophilic mutations in the etiolgy of HELLP syndrome. 
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Table legends 
 
Table 1. Clinical characteristics of the study population.  
Table 2. Maternal genotypes for the 3 mutations/ polymorphisms investigated. Statistical 
analysis was performed by use of chi-suared test, d.f. 1.  
Table 3. Fetal genotypes for the 3 mutations/ polymorphisms investigated. Statistical analysis 
was performed by use of chi-suared test, d.f. 1.  
Table 4. Studies on genetic thrombophilias and risk of HELLP 
Table 5. Association studies of fetal genetic thrombophilias and risk of PE 
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Table 1. Clinical characteristics of the study population.  
 
Characteristic 
 
HELLP (n=71) 
 
Controls (n=79)  p-value 
 
Age (years) 
 
30.0 ± 3.9 30.9 ± 5.0 0.245 
 
Primiparity (%) 
 
n=63 (88.7 %) n=52 (65.8) %  0.229 
 
Week of gestation at delivery 
 
33.0 ± 4.5 39.7 ± 1.3  < 0.001 
 
Infant´s birth weight (g) 
 
1714.7 ± 836.7 3416.5 ± 396.4  < 0.001 
 
Systolic blood pressure 
(mmHg) 
 
168.7 ± 30.0 118.5 ± 6.7 < 0.001 
 
Diastolic blood pressure 
(mmHg) 
 
105.1 ± 17.7 72.4 ± 5.5 < 0.001 
 
Minimal platelet count (G/l) 
 
48 (11 - 97) 249 (150 - 349) < 0.001 
 
AST max (U/l) 
 
104 (23 – 1190) n.d. - 
 
ALT max (U/l) 
 
117 (31 – 1140) n.d. - 
 
LDH max (U/l) 
 
579 (227 – 3460) n.d - 
Values are expressed as mean ± S.D., laboratory parameters as median (range). Normal range for AST 
was 5-15 U/l, for ALT 5-19 U/l.  
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Table 2. Maternal genotypes for the 3 mutations/ polymorphisms investigated.  
  
Prothrombin (20210G>A) 
 
GG                     GA                     AA 
 
       n          %          n          %              n        %       
p OR (95%CI) 
 
HELLP (n=71) 
 
       68      95.8         3        4.2                  0 
 
Controls (n=79) 
 
       76      96.2         3        3.8                  0 
0.894 1.11 (0.23-5.34) 
 
  
Factor V (1691G>A) 
 
GG                     GA                     AA 
      
  n          %          n          %              n       %       
p OR (95%CI) 
 
HELLP (n=71) 
 
     59       83.1       12       16.9                   0 
 
Controls (n=79) 
 
     76       96.2         3         3.8                   0 
0.006 4.45 (1.31-15.13) 
 
  
MTHFR (677C>T) 
 
CC                     CT                     TT 
 
n          %          n          %              n        %        
p OR (95%CI) 
 
HELLP (n=71) 
 
    30       42.3        34       47.9            7       9.9 
 
Controls (n=79) 
 
    35       44.3        29       36.7           15      19  
0.189 0.52 (0.22-1.20) 
 
CI confidence interval, OR odds ratio 
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Table 3. Fetal genotypes for the 3 mutations/ polymorphisms investigated. Frequencies are 
given in parantheses.  
 
  
Prothrombin (20210G>A) 
 
GG                     GA                     AA 
 
n          %          n          %             n        %        
p OR (95%CI) 
 
HELLP children (n=71) 
 
     68       95.8        3         4.2                0 
 
Control children (n=78) 
 
     74       94.9         4        5.1                0 
0.795 0.82 (0.19-3.55) 
 
  
Factor V (1691G>A) 
 
GG                     GA                     AA 
 
n          %          n          %              n        %        
p OR (95%CI) 
 
HELLP children (n=69) 
 
     64        92.8       5         7.2                   0 
 
Control children (n=77) 
 
     72        93.5       5         6.5                   0 
0.857 1.12 (0.34-3,69) 
 
  
MTHFR (677C>T) 
 
CC                     CT                     TT 
 
n          %          n          %              n        %        
p OR (95%CI) 
 
HELLP children (n=68) 
 
    34       50.0        28        41.2            6      8.8 
 
Control children (n=77) 
 
    35       45.4        33        42.9            9     11.7 
0.792 0.75 (0.28-2.01) 
 
CI confidence interval, OR odds ratio 
 
 
 
 
 
